This document summarizes a workshop on analyzing categorical variables in clinical studies. It discusses measures of disease occurrence such as incidence proportion, incidence rate, and prevalence. It provides examples of how to calculate these measures from sample data and describes how to estimate confidence intervals and determine necessary sample sizes. Key topics covered include categorical data, probabilities, rates, cohorts vs open populations, and Bayesian analysis of proportions.
Re-analysis of the Cochrane Library data and heterogeneity challengesEvangelos Kontopantelis
Heterogeneity issues and a re-analysis of the Cochrane Library data. Presented in the 35th Annual Conference of the International Society for Clinical Biostatistics (ISCB35) in Vienna
Home Telehealth Monitoring Outcome Assessment - Kings Fundjohnstamford
Here we show that patients with Chronic Heart Heart who receive Home Telehealth Monitoring equipment have better survival rates and spend more days alive and out of hospital.
Re-analysis of the Cochrane Library data and heterogeneity challengesEvangelos Kontopantelis
Heterogeneity issues and a re-analysis of the Cochrane Library data. Presented in the 35th Annual Conference of the International Society for Clinical Biostatistics (ISCB35) in Vienna
Home Telehealth Monitoring Outcome Assessment - Kings Fundjohnstamford
Here we show that patients with Chronic Heart Heart who receive Home Telehealth Monitoring equipment have better survival rates and spend more days alive and out of hospital.
Clinical trials: quo vadis in the age of covid?Stephen Senn
A discussion of the role of clinical trials in the age of COVID. My contribution to the phastar 2020 life sciences summit https://phastar.com/phastar-life-science-summit
Background: Recently our group performed a cross-sectional study in which 930 general practitioners (GP) in Germany and Denmark received a newly developed questionnaire concerning lower urinary tract symptoms. We developed the questionnaire on the basis of cognitive interviews with GPs and tested the reliability of the German version of the questionnaire in a test-retest process. Methods: 16 GPs took part in the test-retest process and completed the questionnaire twice with a time period of about four weeks between each attempt. The questionnaire consists of 28 questions. The given-answer categories and description fields sum up to a total of 60 items (answers). We assessed the reliability of answers by calculating and interpreting the absolute agreement and Cohen´s Kappa with a 95%-confidence interval for data that were nominal scaled and Pearson´s correlation coefficient for data that were interval scaled, respectively. Results: A total of 27 questions with 59 answer items were included in the analysis. Of them, 13 questions dealt with “management of UI”, six questions addressed the “communication about UI”, four questions asked for the “structure of the practice”, and five questions assessed personal data of the GP. Each more than 50% of the items in the subject areas “management of UI” (53.1%), “communication about UI” (66.6%), “structure of the practice” (57%), and “personal data” (100%) were rated as having high reliability. In summary, 35 of the analyzed items were rated a having a high reliability and 22 items were rated as having a moderate reliability. Conclusion: Given the low number of study participants our results have to be interpreted with caution, but is seems that the developed questionnaire is – for the vast majority of items – a reliable tool for assessing the communication about and the management of female urinary incontinence during a general practitioners’ consultation hour. Before application in future studies we recommend revising one item of the questionnaire in order to gain a higher reliability of this item.
Talk given at ISCB 2016 Birmingham
For indications and treatments where their use is possible, n-of-1 trials represent a promising means of investigating potential treatments for rare diseases. Each patient permits repeated comparison of the treatments being investigated and this both increases the number of observations and reduces their variability compared to conventional parallel group trials.
However, depending on whether the framework for analysis used is randomisation-based or model- based produces puzzling difference in inferences. This can easily be shown by starting on the one hand with the randomisation philosophy associated with the Rothamsted school of inference and building up the analysis through the block + treatment structure approach associated with John Nelder’s theory of general balance (as implemented in GenStat®) or starting on the other hand with a plausible variance component approach through a mixed model. However, it can be shown that these differences are related not so much to modelling approach per se but to the questions one attempts to answer: ranging from testing whether there was a difference between treatments in the patients studied, to predicting the true difference for a future patient, via making inferences about the effect in the average patient.
This in turn yields interesting insight into the long-run debate over the use of fixed or random effect meta-analysis.
Some practical issues of analysis will also be covered in R and SAS®, in which languages some functions and macros to facilitate analysis have been written. It is concluded that n-of-1 hold great promise in investigating chronic rare diseases but that careful consideration of matters of purpose, design and analysis is necessary to make best use of them.
Acknowledgement
This work is partly supported by the European Union’s 7th Framework Programme for research, technological development and demonstration under grant agreement no. 602552. “IDEAL”
Various designs of observational studies (prospective, retrospective, and cross-sectional) and analytical studies (clinical trials and laboratory experiments), and guidelines to choose appropriate sample size
The statistical revolution of the 20th century was largely concerned with developing methods for analysing small datasets. Student’s paper of 1908 was the first in the English literature to address the problem of second order uncertainty (uncertainty about the measures of uncertainty) seriously and was hailed by Fisher as heralding a new age of statistics. Much of what Fisher did was concerned with problems of what might be called ‘small data’, not only as regards efficient analysis but also as regards efficient design and in addition paying close attention to what was necessary to measure uncertainty validly.
I shall consider the history of some of these developments, in particular those that are associated with what might be called the Rothamsted School, starting with Fisher and having its apotheosis in John Nelder’s theory of General Balance and see what lessons they hold for the supposed ‘big data’ revolution of the 21st century.
An early and overlooked causal revolution in statistics was the development of the theory of experimental design, initially associated with the "Rothamstead School". An important stage in the evolution of this theory was the experimental calculus developed by John Nelder in the 1960s with its clear distinction between block and treatment factors in designed experiments. This experimental calculus produced appropriate models automatically from more basic formal considerations but was, unfortunately, only ever implemented in Genstat®, a package widely used in agriculture but rarely so in medical research. In consequence its importance has not been appreciated and the approach of many statistical packages to designed experiments is poor. A key feature of the Rothamsted School approach is that identification of the appropriate components of variation for judging treatment effects is simple and automatic.
The impressive more recent causal revolution in epidemiology, associated with Judea Pearl, seems to have no place for components of variation, however. By considering the application of Nelder’s experimental calculus to Lord’s Paradox, I shall show that this reveals that solutions that have been proposed using the more modern causal calculus are problematic. I shall also show that lessons from designed clinical trials have important implications for the use of historical data and big data more generally.
Clinical trials: quo vadis in the age of covid?Stephen Senn
A discussion of the role of clinical trials in the age of COVID. My contribution to the phastar 2020 life sciences summit https://phastar.com/phastar-life-science-summit
Background: Recently our group performed a cross-sectional study in which 930 general practitioners (GP) in Germany and Denmark received a newly developed questionnaire concerning lower urinary tract symptoms. We developed the questionnaire on the basis of cognitive interviews with GPs and tested the reliability of the German version of the questionnaire in a test-retest process. Methods: 16 GPs took part in the test-retest process and completed the questionnaire twice with a time period of about four weeks between each attempt. The questionnaire consists of 28 questions. The given-answer categories and description fields sum up to a total of 60 items (answers). We assessed the reliability of answers by calculating and interpreting the absolute agreement and Cohen´s Kappa with a 95%-confidence interval for data that were nominal scaled and Pearson´s correlation coefficient for data that were interval scaled, respectively. Results: A total of 27 questions with 59 answer items were included in the analysis. Of them, 13 questions dealt with “management of UI”, six questions addressed the “communication about UI”, four questions asked for the “structure of the practice”, and five questions assessed personal data of the GP. Each more than 50% of the items in the subject areas “management of UI” (53.1%), “communication about UI” (66.6%), “structure of the practice” (57%), and “personal data” (100%) were rated as having high reliability. In summary, 35 of the analyzed items were rated a having a high reliability and 22 items were rated as having a moderate reliability. Conclusion: Given the low number of study participants our results have to be interpreted with caution, but is seems that the developed questionnaire is – for the vast majority of items – a reliable tool for assessing the communication about and the management of female urinary incontinence during a general practitioners’ consultation hour. Before application in future studies we recommend revising one item of the questionnaire in order to gain a higher reliability of this item.
Talk given at ISCB 2016 Birmingham
For indications and treatments where their use is possible, n-of-1 trials represent a promising means of investigating potential treatments for rare diseases. Each patient permits repeated comparison of the treatments being investigated and this both increases the number of observations and reduces their variability compared to conventional parallel group trials.
However, depending on whether the framework for analysis used is randomisation-based or model- based produces puzzling difference in inferences. This can easily be shown by starting on the one hand with the randomisation philosophy associated with the Rothamsted school of inference and building up the analysis through the block + treatment structure approach associated with John Nelder’s theory of general balance (as implemented in GenStat®) or starting on the other hand with a plausible variance component approach through a mixed model. However, it can be shown that these differences are related not so much to modelling approach per se but to the questions one attempts to answer: ranging from testing whether there was a difference between treatments in the patients studied, to predicting the true difference for a future patient, via making inferences about the effect in the average patient.
This in turn yields interesting insight into the long-run debate over the use of fixed or random effect meta-analysis.
Some practical issues of analysis will also be covered in R and SAS®, in which languages some functions and macros to facilitate analysis have been written. It is concluded that n-of-1 hold great promise in investigating chronic rare diseases but that careful consideration of matters of purpose, design and analysis is necessary to make best use of them.
Acknowledgement
This work is partly supported by the European Union’s 7th Framework Programme for research, technological development and demonstration under grant agreement no. 602552. “IDEAL”
Various designs of observational studies (prospective, retrospective, and cross-sectional) and analytical studies (clinical trials and laboratory experiments), and guidelines to choose appropriate sample size
The statistical revolution of the 20th century was largely concerned with developing methods for analysing small datasets. Student’s paper of 1908 was the first in the English literature to address the problem of second order uncertainty (uncertainty about the measures of uncertainty) seriously and was hailed by Fisher as heralding a new age of statistics. Much of what Fisher did was concerned with problems of what might be called ‘small data’, not only as regards efficient analysis but also as regards efficient design and in addition paying close attention to what was necessary to measure uncertainty validly.
I shall consider the history of some of these developments, in particular those that are associated with what might be called the Rothamsted School, starting with Fisher and having its apotheosis in John Nelder’s theory of General Balance and see what lessons they hold for the supposed ‘big data’ revolution of the 21st century.
An early and overlooked causal revolution in statistics was the development of the theory of experimental design, initially associated with the "Rothamstead School". An important stage in the evolution of this theory was the experimental calculus developed by John Nelder in the 1960s with its clear distinction between block and treatment factors in designed experiments. This experimental calculus produced appropriate models automatically from more basic formal considerations but was, unfortunately, only ever implemented in Genstat®, a package widely used in agriculture but rarely so in medical research. In consequence its importance has not been appreciated and the approach of many statistical packages to designed experiments is poor. A key feature of the Rothamsted School approach is that identification of the appropriate components of variation for judging treatment effects is simple and automatic.
The impressive more recent causal revolution in epidemiology, associated with Judea Pearl, seems to have no place for components of variation, however. By considering the application of Nelder’s experimental calculus to Lord’s Paradox, I shall show that this reveals that solutions that have been proposed using the more modern causal calculus are problematic. I shall also show that lessons from designed clinical trials have important implications for the use of historical data and big data more generally.
Mesurement of morbidity (prevalence) presentationDrsadhana Meena
measurement of morbidity (prevalence ) presentation by dr. sadhana, sms medical college , jaipur
included all aspects related to prevalence - objectives,types,significance ,comparison between prevalence and incidence , practical example of prevalence.
The STUDY of the DISTRIBUTION and DETERMINANTS of HEALTH-RELATED STATES in specified POPULATIONS, and the application of this study to CONTROL of health problems."
P-values the gold measure of statistical validity are not as reliable as many...David Pratap
This is an article that appeared in the NATURE as News Feature dated 12-February-2014. This article was presented in the journal club at Oman Medical College , Bowshar Campus on December, 17, 2015. This article was presented by Pratap David , Biostatistics Lecturer.
Study of the distribution and determinants of
health-related states or events in specified populations and the application of this study to control health problems.
John M. Last, Dictionary of Epidemiology
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Ct lecture 5. descriptive analysis of categorical variables
1. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Descriptive analysis
of categorical variables
Tuan V. Nguyen
Professor and NHMRC Senior Research Fellow
Garvan Institute of Medical Research
University of New South Wales
Sydney, Australia
2. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
What we are going to learn
• Categorical data
• Probability
• Statistical description of
– Prevalence
– Incidence
– Rate
3. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Measurement and comparison
To find out whether a community is healthy or
unhealthy:
• first measure one or more indicators of health
(deaths, new cases of disease, etc)
• compare the results with another community or
group.
4. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Measures of Disease Occurrence
• Incidence proportion (risk)
• Incidence rate (density)
• Prevalence
All three are loosely called “rates” (but only the
second is a true rate)
5. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Types of populations
We measure disease occurrence in two types of
populations:
• Closed populations ! “cohorts”
• Open populations
6. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
6
Cohort word origin
(Latin cohors) basic
tactical unit of a
Roman legion
Epi cohort ≡ a
group of individuals
followed over time
Closed population = cohort
7. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Inflow (immigration,
births)
• Outflow (emigration,
death)
• An open population in
“steady
state” (constant size)
is said to be
stationary
Open population
8. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• “Rates” are composed of
numerators and
denominators
• Numerator ! case count
Incidence count ! onsets
Prevalence count ! old + new
cases
• Denominators ! reflection
of population size
Numerators and denominators
9. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Denominators
Denominators:
reflection of population
size
10. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Synonyms: risk, cumulative incidence,
attack rate
• Interpretation: average risk
study
of
beginning
at
risk
@
no.
over time
onsets
of
no.
IP =
Can be calculated only in cohorts
Incidence proportion
11. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Objective: estimate risk of uterine cancer
• Recruit cohort of 1000 women
• 100 had hysterectomies, leaving 900 at risk
• Follow at risk individuals for 10 years
• Observe 10 onsets of uterine cancer
women
900
women
10
risk
@
no.
onsets
of
no.
IP =
=
10-year average risk is .011 or 1.1%.
0111
.
0
=
Example of IP
12. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Synonyms: incidence density, person-time rate
• Interpretation A: “Speed” at which events occur
• Interpretation B: When disease is rare:
rate per person-year ≈ one-year risk
• Calculated differently in closed and open
populations
risk
@
time
-
person
of
Sum
onsets
no.
IR =
Incidence rate
13. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Objective: estimate rate of uterine cancer
• Recruit cohort of 1000 women
• 100 had hysterectomies, leaving 900 at risk
• Follow at risk individuals for 10 years
• Observe 10 onsets of uterine cancer
time
-
person
onsets
of
no.
IR =
Rate is .00111 per year or 11.1 per 10,000 years
years
9000
10
=
years
10
women
900
women
10
×
=
year
.00111
=
Example of IP
14. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Individual follow-up over time
years
50
years
25
onsets
2
+
=
time
-
person
onsets
IR
∑
=
years
-
person
100
per
2.67
years
-
person
per
0267
.
0 =
=
years
75
onsets
2
=
15. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Rate
Mortality
1
expectacy
Life =
In stationary populations, and in cohorts with
complete follow-up, the mortality rate is the
reciprocal of life expectancy (and vice versa).
Example: for a mortality rate of .0267 per year
years
5
.
37
year
.0267
1
expectacy
Life =
=
Mortality and life expectancy
16. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
years
37.5
2
years
50)
(25
expectancy
life
has
cohort
This =
+
year
0267
.
0
years
50)
(25
deaths
2
of
rate
mortality
a
has
cohort
This 1
−
=
+
17. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
years
-
person
100,000
per
877
=
n
observatio
of
duration
size
population
Avg
onsets
IR
×
=
-1
year
deaths
008770
.
0
=
Example: 2,391,630 deaths in 1999 (one year)
Population size = 272,705,815
year
1
persons
5
272,705,81
deaths
2,391,630
IR
×
=
Incidence rate in open population
18. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Point prevalence ≡ prevalence at a particular point in
time
• Period prevalence ≡ prevalence over a period of time
• Interpretation A: proportion with condition
• Interpretation B: probability a person selected at
random will have the condition
people
of
no.
cases
new
and
old
no.
Prevalence=
Prevalence
19. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
• Recruit 1000 women
• Ascertain: 100 with hysterectomies
people
of
no.
cases
no.
Prevalence=
Prevalence in sample is 10%
10
.
0
=
people
1000
people
100
=
Example of prevalence
20. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Increase incidence ! increase
inflow
Increase average duration of
disease ! decreased outflow
Ways to increase prevalence
Dynamic prevalence
21. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
duration)
(average
rate)
(incidence
prevalence ×
≈
Example:
• Incidence rate = 0.01 / year
• Average duration of the illness = 2 years.
• Prevalence ≈ 0.01 / year × 2 years = 0.02
When disease rare & population stationary
Prevalence and incidence
22. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Estimation of 95% confidence interval
23. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Proportions
• Proportion of event in the sample, denoted “p hat”:
where x = no. of events and n = sample size
n
x
p =
ˆ
24. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Proportion, cont
Two of 10 individuals in the sample have a risk factor
for disease X
The prevalence of this risk factor in the sample is:
(or10%)
1
.
0
10
2
ˆ =
=
=
n
x
p
25. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Inference about a Proportion
How good is sample proportion at estimating
population proportion p?
Consider what would happen if we took repeated
samples, each of size n, from the population? How
would sample proportions be distributed?
26. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
p
q
n
pq
p
N
p
−
=
⎟
⎟
⎠
⎞
⎜
⎜
⎝
⎛
1
where
,
~
ˆ
Normal Approximation for Proportions
27. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Normal approximation
H0: p = p0 vs. Ha: p ! p0 where p0 represents the
proportion specified by the null hypothesis
Test statistic
ˆ
0
0
0
stat
n
q
p
p
p
z
−
=
28. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Example
n = 57 finds 17 smokers (p-hat = 17 / 57 = 0.2982).
The national average for smoking prevalence is 0.25.
Is the proportion in the sample significantly different
than the national average?
H0:p = 0.25 vs. Ha: p ≠ 0.25
The sample proportion is not significantly different
than the national average.
84
.
0
57
75
.
25
.
25
.
2982
.
ˆ
0
0
0
stat =
⋅
−
=
−
=
n
q
p
p
p
z
29. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Confidence Interval for Proportion
p± z1−α
2
⋅
p
q
n
where
x =
x + 2,
n = n + 4,
p =
x
n
, and
q =1−
p
This method is called the “plus four method”
because it adds four imaginary points during
calculations. It is much more accurate than the
traditional Normal method.
A 1−α(100%) confidence interval for p is:
30. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Confidence Interval, example
)
4277
.
,
1953
(.
1162
.
3115
.
)
0593
)(.
96
.
1
(
3115
.
~
for
CI
95%
confidence
95%
for
96
.
1
0593
.
61
)
6885
)(.
3115
(.
~
~
~
6885
.
3115
.
1
~
;
3115
.
61
19
~
61
4
57
4
~
;
19
2
17
2
~
~
~
=
±
=
±
=
⋅
±
=
=
=
=
=
=
−
=
=
=
=
+
=
+
=
=
+
=
+
=
p
p
SE
z
p
p
z
n
q
p
SE
q
p
n
n
x
x
Based on n = 57 and x = 17, the 95% CI for the
prevalence of smoking in the population is:
31. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Sample Size and Power
Three approaches:
• n needed to estimate p with margin of error m (for
confidence interval)
• n needed to test H0 at given α level and power
• The power of testing H0 under stated conditions
32. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
n need to achieve margin of error m
• where p* represent an educated guess for population
proportion p (when no educated guess for p* is
available, let p* = .5)
• Round up to next integer to ensure stated precision
2
*
*
2
1 2
m
q
p
z
n
α
−
=
33. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
n need to achieve m, example
Suppose our educated guess for the proportion is
p* = 0.30
897
896.4
03
.
)
70
)(.
30
)(.
96
.
1
(
2
2
⇒
=
=
n
For margin of error of .03, use:
323
322.7
05
.
)
70
)(.
30
)(.
96
.
1
(
2
2
⇒
=
=
n
For margin of error of .05, use:
34. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
n to test H0: p = p0
where
• α ≡ alpha level of the test (two-sided)
• 1 – β ≡ power of the test
• p0 ≡ proportion under the null hypothesis
• p1 ≡ proportion under the alternative hypothesis
2
0
1
1
1
1
0
0
1 2
⎟
⎟
⎟
⎠
⎞
⎜
⎜
⎜
⎝
⎛
−
+
=
−
−
p
p
q
p
z
q
p
z
n
β
α
35. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
n to test H0: p = p0, example
How large a sample is needed to test H0: p = 0.21 against
Ha: p = 0.31 at α = 0.05 (two-sided) with 90% power?
194
3
.
193
21
.
0
31
.
0
)
69
.
0
)(
31
.
0
(
28
.
1
)
79
.
0
)(
21
.
0
(
96
.
1
2
⇒
=
⎟
⎟
⎠
⎞
⎜
⎜
⎝
⎛
−
+
=
n
! means round up to ensure stated power
36. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Conditions for Inference
• Sampling independence
• Valid information
• The plus-four confidence
interval requires at least 10
observations
• The z test of H0: p = p0 requires
np0q0 ! 5
I'd rather have a sound
judgment than a talent.
Mark Twain
37. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Bayesian analysis of proportion
38. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Review
• When X ∼ Binomial(n, p) we know that
• p = X/n is the MLE for p
• Var(p) = p(1 − p)/n
• Wald interval for p
p± Z1−α/2 p 1− p
( )
39. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Problems of Wald CI
• The Wald interval performs terribly
• Coverage probability varies wildly, sometimes being
quite low for certain values of n even when p is not
near the boundaries
– Example, when p = .5 and n = 40 the actual coverage of a
95% interval is only 92%
• When p is small or large, coverage can be quite poor
even for extremely large values of n
– Example, when p = .005 and n = 1, 876 the actual cov-
erage rate of a 95% interval is only 90%
40. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Simple adjustment
• A simple fix for the problem is to add 2 successes and
2 failures
• That is let p = (X + 2) / (n + 4)
• Lead to the Agresti-Coull interval
p± Z1−α/2 p 1− p
( )
41. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Bayesian analysis
• Bayesian statistics posits a prior on the parameter of
interest
• All inferences are then performed on the distribution
of the parameter given the data, called the posterior
• In general
Posterior ∝ Likelihood × Prior
• The likelihood is the factor by which our prior beliefs
are updated to produce conclusions in the light of the
data
42. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Beta priors
• The beta distribution is the default prior for parame-
ters between 0 and 1
• The beta density depends on two parameters α and
β
• The mean of the beta density is α/(α + β)
• The variance of the beta density is
• The uniform density is the special case where α = β
= 1
between 0 and 1.
beta density depends on two parameters α a
Γ(α + β)
Γ(α)Γ(β)
pα−1(1 − p)β−1 for 0 ≤ p ≤ 1
mean of the beta density is α/(α + β)
variance of the beta density is
αβ
(α + β)2(α + β + 1)
uniform density is the special case where α =
43. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Some beta distributions
0.0 0.4 0.8
2
6
10
p
density
alpha = 0.5 beta = 0.5
0.0 0.4 0.8
0
5
10
15
p
density
alpha = 0.5 beta = 1
0.0 0.4 0.8
0
10
20
p
density
alpha = 0.5 beta = 2
0.0 0.4 0.8
0
5
10
15
p
density
alpha = 1 beta = 0.5
0.0 0.4 0.8
0.6
1.0
1.4
p
density
alpha = 1 beta = 1
0.0 0.4 0.8
0.0
1.0
2.0
p
density
alpha = 1 beta = 2
0.0 0.4 0.8
0
10
20
p
density
alpha = 2 beta = 0.5
0.0 0.4 0.8
0.0
1.0
2.0
p
density
alpha = 2 beta = 1
0.0 0.4 0.8
0.0
1.0
p
density
alpha = 2 beta = 2
44. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Posterior
• Suppose that we chose values of α and β so that the
beta prior is indicative of our degree of belief regard-
ing p in the absence of data
• Then using the rule that
Posterior ∝ Likelihood × Prior
and throwing out anything that doesn’t depend on p, we
have that
terior
uppose that we chose values of α and β so that th
eta prior is indicative of our degree of belief regar
g p in the absence of data
hen using the rule that
Posterior ∝ Likelihood × Prior
nd throwing out anything that doesn’t depend on
e have that
Posterior ∝ px(1 − p)n−x × pα−1(1 − p)β−1
= px+α−1(1 − p)n−x+β−1
his density is just another beta density with param
45. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Posterior mean
• This density is just another beta density with param-
eters α* =x+α and β =n−x+β
Posterior mean
• Posterior mean
E[p | X] =
α̃
α̃ + β̃
=
x + α
x + α + n − x + β
=
x + α
n + α + β
=
x
n
×
n
n + α + β
+
α
α + β
×
α + β
n + α + β
= MLE × π + Prior Mean × (1 − π)
46. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Posterior variance
• Posterior variance is
Posterior variance
• The posterior variance is
Var(p | x) =
α̃β̃
(α̃ + β̃)2(α̃ + β̃ + 1)
=
(x + α)(n − x + β)
(n + α + β)2(n + α + β + 1)
• Let p̃ = (x + α)/(n + α + β) and ñ = n + α + β then we have
Var(p | x) =
p̃(1 − p̃)
ñ + 1
• Let p* = (x + α)/(n + α + β) and n* = n + α + β then
we have
Var(p | x) = p*(1 – p*) / (n* + 1)
47. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
Jeffreys prior
• The “Jeffrey’s prior” has some theoretical benefits
puts α = β = 0.5
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
p
prior,
likelihood,
posterior Prior
Likelihood
Posterior
alpha = 0.5 beta = 0.5
48. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
p
prior,
likelihood,
posterior
Prior
Likelihood
Posterior
alpha = 1 beta = 1
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
p
prior,
likelihood,
posterior
Prior
Likelihood
Posterior
alpha = 2 beta = 2
49. Workshop on Analysis of Clinical Studies – Can Tho University of Medicine and Pharmacy – April 2012
R code
• Install the binom package, then the command
library(binom)
binom.bayes(13, 20, type = "highest")
gives the HPD interval. The default credible level is 95%
and the default prior is the Jeffrey’s prior.